Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$201.12 -3.8%	$195.65	$153.58 ▼ $218.66	$355.05B	0.61	5.27 million shs	10.09 million shs
BMY Bristol-Myers Squibb	$59.22 -3.0%	$58.36	$39.35 ▼ $63.33	$120.18B	0.43	12.17 million shs	10.97 million shs
BNTX BioNTech	$97.05 -3.6%	$112.45	$76.53 ▼ $131.49	$23.29B	0.3	784,506 shs	552,218 shs
MRK Merck & Co., Inc.	$87.88 -4.8%	$92.60	$81.04 ▼ $134.63	$221.99B	0.35	10.30 million shs	20.63 million shs
PFE Pfizer	$25.56 -2.2%	$26.14	$24.48 ▼ $31.54	$144.96B	0.61	36.71 million shs	47.48 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	-3.88%	-5.93%	-0.45%	+11.73%	+12.67%
BMY Bristol-Myers Squibb	-3.07%	-1.20%	+6.04%	+2.53%	+13.34%
BNTX BioNTech	-3.57%	-1.93%	-19.13%	-14.97%	+4.35%
MRK Merck & Co., Inc.	-4.89%	-7.19%	-1.69%	-11.63%	-29.88%
PFE Pfizer	-2.19%	-2.84%	-2.88%	-4.41%	-6.82%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.7455 of 5 stars	2.5	5.0	3.3	3.9	3.5	2.5	1.3
BMY Bristol-Myers Squibb	3.8096 of 5 stars	1.2	3.0	4.2	4.0	3.0	3.3	0.0
BNTX BioNTech	3.4135 of 5 stars	4.4	5.0	0.0	0.0	2.7	0.8	0.0
MRK Merck & Co., Inc.	5 of 5 stars	4.3	3.0	4.2	3.9	2.7	3.3	3.8
PFE Pfizer	4.9138 of 5 stars	2.3	3.0	4.2	4.2	2.8	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.92	Moderate Buy	$211.45	5.14% Upside
BMY Bristol-Myers Squibb	2.32	Hold	$57.86	-2.30% Downside
BNTX BioNTech	2.89	Moderate Buy	$143.73	48.10% Upside
MRK Merck & Co., Inc.	2.65	Moderate Buy	$117.12	33.27% Upside
PFE Pfizer	2.63	Moderate Buy	$31.92	24.89% Upside

Current Analyst Ratings Breakdown

Latest BMY, PFE, MRK, ABBV, and BNTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/18/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/17/2025	ABBV AbbVie	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/13/2025	BNTX BioNTech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$145.00
3/12/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/11/2025	BNTX BioNTech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$145.00 ➝ $139.00
3/11/2025	BNTX BioNTech	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$171.44 ➝ $171.44
3/11/2025	BNTX BioNTech	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$130.00 ➝ $143.00
3/10/2025	PFE Pfizer	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/5/2025	ABBV AbbVie	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$210.00 ➝ $240.00
3/4/2025	ABBV AbbVie	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$200.00 ➝ $223.00
2/18/2025	MRK Merck & Co., Inc.	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$128.00 ➝ $105.00

(Data available from 3/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	6.30	$14.86 per share	13.53	$1.90 per share	105.85
BMY Bristol-Myers Squibb	$48.30B	2.49	$6.25 per share	9.48	$8.08 per share	7.33
BNTX BioNTech	$2.75B	8.47	$4.17 per share	23.25	$92.17 per share	1.05
MRK Merck & Co., Inc.	$64.17B	3.46	$3.05 per share	28.82	$14.85 per share	5.92
PFE Pfizer	$63.63B	2.28	$4.01 per share	6.38	$15.81 per share	1.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.40	83.80	14.39	1.62	7.59%	296.28%	12.65%	4/25/2025 (Estimated)
BMY Bristol-Myers Squibb	-$8.95B	-$4.42	N/A	9.72	2.07	-18.53%	13.93%	2.46%	4/24/2025 (Estimated)
BNTX BioNTech	$1.01B	-$3.00	N/A	N/A	N/A	-15.16%	-2.35%	-2.05%	5/5/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.73	13.06	8.88	0.77	26.67%	45.35%	17.36%	4/24/2025 (Estimated)
PFE Pfizer	$8.03B	$1.41	18.13	8.44	0.64	12.62%	19.47%	8.09%	4/29/2025 (Estimated)

Latest BMY, PFE, MRK, ABBV, and BNTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/10/2025	Q4 24	BNTX BioNTech	$0.38	$1.08	+$0.70	$1.15	$1.24 billion	$1.19 billion
2/6/2025	Q4 2024	BMY Bristol-Myers Squibb	$1.47	$1.67	+$0.20	$0.04	$11.57 billion	N/A
2/4/2025	Q4 2024	MRK Merck & Co., Inc.	$1.85	$1.72	-$0.13	$1.48	$15.51 billion	$15.62 billion
2/4/2025	Q4 2024	PFE Pfizer	$0.48	$0.63	+$0.15	$0.07	$17.26 billion	$17.76 billion
1/31/2025	Q4 24	ABBV AbbVie	$2.98	$2.16	-$0.82	-$0.02	$14.81 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.26%	+6.04%	273.33%	53 Years
BMY Bristol-Myers Squibb	$2.48	4.19%	+6.38%	N/A	17 Years
BNTX BioNTech	$1.53	1.58%	N/A	N/A	N/A
MRK Merck & Co., Inc.	$3.24	3.69%	+5.73%	48.14%	14 Years
PFE Pfizer	$1.72	6.73%	+2.50%	121.99%	16 Years

Latest BMY, PFE, MRK, ABBV, and BNTX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/13/2025	ABBV AbbVie	quarterly	$1.64	3.4%	4/15/2025	4/15/2025	5/15/2025
3/3/2025	BMY Bristol-Myers Squibb	quarterly	$0.62	4.14%	4/4/2025	4/4/2025	5/1/2025
1/28/2025	MRK Merck & Co., Inc.	quarterly	$0.81	3.32%	3/17/2025	3/17/2025	4/7/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	17.94	0.66	0.55
BMY Bristol-Myers Squibb	2.90	1.25	1.15
BNTX BioNTech	0.01	7.33	7.21
MRK Merck & Co., Inc.	0.79	1.36	1.15
PFE Pfizer	0.63	1.00	0.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
BMY Bristol-Myers Squibb	76.41%
BNTX BioNTech	15.52%
MRK Merck & Co., Inc.	76.07%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.25%
BMY Bristol-Myers Squibb	0.09%
BNTX BioNTech	19.20%
MRK Merck & Co., Inc.	0.09%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	50,000	1.77 billion	1.76 billion	Optionable
BMY Bristol-Myers Squibb	34,300	2.03 billion	2.03 billion	Optionable
BNTX BioNTech	6,133	239.97 million	193.71 million	Optionable
MRK Merck & Co., Inc.	69,000	2.53 billion	2.53 billion	Optionable
PFE Pfizer	83,000	5.67 billion	5.66 billion	Optionable

BMY, PFE, MRK, ABBV, and BNTX Headlines

Recent News About These Companies

Pfizer Is Trading As If It's 2009 Again

March 25 at 4:04 PM | seekingalpha.com

Pfizer (NYSE:PFE) Shares Down 1.1% - Time to Sell?

March 25 at 3:41 PM | marketbeat.com

5 Large Drug Stocks to Watch as Industry Recovers

March 25 at 7:50 AM | zacks.com

Pfizer Inc. (NYSE:PFE) Stock Holdings Lessened by FineMark National Bank & Trust

March 25 at 6:11 AM | marketbeat.com

Congress Wealth Management LLC DE Trims Stock Position in Pfizer Inc. (NYSE:PFE)

March 25 at 5:13 AM | marketbeat.com

Analysts Issue Forecasts for Pfizer's Q2 Earnings (NYSE:PFE)

March 25 at 2:56 AM | americanbankingnews.com

Zacks Research Issues Negative Outlook for Pfizer Earnings

March 25 at 2:22 AM | marketbeat.com

China promotes business potential to Apple, Pfizer and other US companies

March 24 at 5:24 PM | dunyanews.tv

Is Pfizer Inc. (PFE) The Best Healthcare Dividend Stock to Invest in?

March 24 at 5:24 PM | msn.com

Is Pfizer (PFE) The Best Affordable Stock To Buy According To Hedge Funds?

March 24 at 5:24 PM | msn.com

Pfizer (NYSE:PFE) Shares Down 0.7% - Here's What Happened

March 24 at 1:53 PM | marketbeat.com

Pfizer Is a Dirt-Cheap High-Yield Stock, But Is It a Buy?

March 24 at 9:40 AM | zacks.com

Haverford Trust Co Trims Stock Holdings in Pfizer Inc. (NYSE:PFE)

March 24 at 7:25 AM | marketbeat.com

Prudential Financial Inc. Has $183.79 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

March 24 at 7:23 AM | marketbeat.com

China Highlights Business Opportunities to America’s Apple (AAPL) and Pfizer

March 24 at 7:11 AM | tipranks.com

Woodmont Investment Counsel LLC Purchases 25,505 Shares of Pfizer Inc. (NYSE:PFE)

March 24 at 6:32 AM | marketbeat.com

Corebridge Financial Inc. Sells 62,333 Shares of Pfizer Inc. (NYSE:PFE)

March 24 at 6:31 AM | marketbeat.com

Hillsdale Investment Management Inc. Boosts Stock Holdings in Pfizer Inc. (NYSE:PFE)

March 24 at 5:11 AM | marketbeat.com

Sei Investments Co. Boosts Stake in Pfizer Inc. (NYSE:PFE)

March 24 at 5:10 AM | marketbeat.com

Zacks Research Has Negative Estimate for Pfizer Q2 Earnings

March 24 at 2:21 AM | marketbeat.com

China Courts Apple, Pfizer, Eli Lilly Amid US Pressure, Vice Premier Says Beijing 'Will Continue To Improve The Business Environment'

March 23 at 10:06 PM | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Price Targets on NVIDIA Rise in Front of Earnings
By Sarah Horvath | February 24, 2025
View Price Targets on NVIDIA Rise in Front of Earnings
Warren Buffett Swaps VOO for This Reliable Dividend Stock
By Sarah Horvath | March 7, 2025
View Warren Buffett Swaps VOO for This Reliable Dividend Stock
NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
By Thomas Hughes | March 12, 2025
View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
Archer Aviation Stock Skids: Mistaking Progress for Bad News?
By Chris Markoch | February 24, 2025
View Archer Aviation Stock Skids: Mistaking Progress for Bad News?
AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
By Chris Markoch | March 23, 2025
View AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market

BMY, PFE, MRK, ABBV, and BNTX Company Descriptions

AbbVie NYSE:ABBV

$201.12 -8.05 (-3.85%)

Closing price 03/25/2025 03:58 PM Eastern

Extended Trading

$201.25 +0.13 (+0.06%)

As of 03/25/2025 07:59 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Bristol-Myers Squibb NYSE:BMY

$59.22 -1.83 (-3.00%)

Closing price 03/25/2025 03:58 PM Eastern

Extended Trading

$59.25 +0.03 (+0.05%)

As of 03/25/2025 07:56 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

BioNTech NASDAQ:BNTX

$97.05 -3.59 (-3.57%)

Closing price 03/25/2025 04:00 PM Eastern

Extended Trading

$97.75 +0.70 (+0.73%)

As of 03/25/2025 07:56 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Merck & Co., Inc. NYSE:MRK

$87.88 -4.43 (-4.80%)

Closing price 03/25/2025 03:58 PM Eastern

Extended Trading

$88.01 +0.13 (+0.15%)

As of 03/25/2025 07:59 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Pfizer NYSE:PFE

$25.56 -0.58 (-2.22%)

Closing price 03/25/2025 03:58 PM Eastern

Extended Trading

$25.63 +0.07 (+0.27%)

As of 03/25/2025 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BMY, PFE, MRK, ABBV, and BNTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BMY, PFE, MRK, ABBV, and BNTX Earnings

Compare Dividends

Latest BMY, PFE, MRK, ABBV, and BNTX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BMY, PFE, MRK, ABBV, and BNTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BMY, PFE, MRK, ABBV, and BNTX Company Descriptions

AbbVie NYSE:ABBV

Bristol-Myers Squibb NYSE:BMY

BioNTech NASDAQ:BNTX

Merck & Co., Inc. NYSE:MRK

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools